There are several trials on prevention of diabetes with TZDs.
几项临床试验开展了噻唑烷二酮类药物预防糖尿病的研究。
This result is particularly interesting because in men, loop diuretics or TZDs alone did not confer significant risks.
这一结果特别令人感兴趣，因为男性，单独使用髓袢利尿药或噻唑烷二酮类药物，都不能形成显著的危害。
Men with diabetes taking both loop diuretics and TZDs may also be at increased risk of fractures, according to the research.
依照这一研究，患有糖尿病的男性在同时服用髓袢利尿药和噻唑烷二酮类药物时也会增加骨折的危险。
Thiazolidinediones (TZDs) are a new class of agents commonly used for the treatment of patients with type 2 diabetes or insulin resistance.
噻唑烷二酮类药物是一类新的治疗2型糖尿病和胰岛素抵抗的药物。
CONCLUSION: Postmenopausal women taking TZDs and the subset of men taking both loop diuretics and TZDs were at increased risk for fractures.
结论：绝经后女性服用TZD与男性同时服用髓袢利尿剂和TZD骨折风险均增加。
Exposure to both loop diuretics and TZDs, glucocorticoids, and insulin and limited mobility and lower-extremity amputation were associated with fractures in men.
在男性，同时服用髓袢利尿剂、TZD、糖皮质激素和胰岛素并伴活动受限和下肢截肢的其骨折风险增加具有统计学意义。
For more than 10 years, thiazolidinediones (TZDs) have been prescribed for diabetes therapy in the U. S. on the sole basis of evidence that they improve glycemic control.
在美国，基于噻唑啉二酮类药物能提高人体控制血糖的能力，10多年来该药物一直用于糖尿病的治疗。
Let us say that at first the TZDs which is the rosiglitazone and the pioglitazones had problems which I think will decrease the interest yet on the protection of diabetes.
让我们先谈一下TZD类罗格列酮和匹格列酮，我想它们均有使人们对其防治糖尿病的兴趣减少的问题。
A new study has revealed that postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures.
一项新的研究显示患有糖尿病的绝经妇女在服用噻唑烷二酮类药物，包括匹格列酮与罗格列酮时，会增加骨折的危险。
RESULTS: We found statistically significant increased odds of exposure to TZDs, glucocorticoids, loop diuretics, and self-reported limited mobility for women 50 yr of age and older with fractures.
结果：研究表明50岁及以上的女性服用TZD、糖皮质激素，髓袢利尿剂和自报活动受限的其骨折风险增加具有统计学意义。
RESULTS: We found statistically significant increased odds of exposure to TZDs, glucocorticoids, loop diuretics, and self-reported limited mobility for women 50 yr of age and older with fractures.
结果：研究表明50岁及以上的女性服用TZD、糖皮质激素，髓袢利尿剂和自报活动受限的其骨折风险增加具有统计学意义。
应用推荐